Healthcare / Drug Manufacturers - Specialty & GenericCboe CA
$1.67
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $13.1M · quality 35.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$609M
P/E
N/A
•EV/EBITDA
43.7x
↑ROE
-36.6%
↓Gross Margin
50.3%
↑Debt/Equity
0.71
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-2.2%
FCF CAGR
—
FCF margin
1.4%
FCF / Net income
-0.05x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $821.5M · net income $-257.9M · FCF $11.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $821.5M | $821.5M | $878.6M | $938.5M | $879.4M |
| Net Income | $-257.9M | $-257.9M | $-341.9M | $-117.3M | $-269.2M |
| EBITDA | $23.5M | $23.5M | $-94.3M | $239.2M | $36.4M |
| EPS | -0.71 | -0.71 | -0.95 | -0.34 | -0.81 |
| Gross Margin | 50.3% | 50.3% | 50.5% | 50.6% | 48.1% |
| Operating Margin | 9.3% | 9.3% | 10.3% | 15.3% | 7.6% |
| Net Margin | -31.4% | -31.4% | -38.9% | -12.5% | -30.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.71 | 0.71 | 0.55 | 0.44 | 0.37 |
| Current Ratio | 3.32 | 3.32 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $11.6M | $11.6M | $13.1M | $73.4M | $-24.8M |
| Returns | |||||
| ROE | -36.6% | -36.6% | -35.9% | -9.5% | -20.1% |
| Valuation | |||||
| EV/EBITDA | 43.67 | 43.67 | — | 10.88 | 48.40 |
| P/B | 0.86 | 0.86 | 0.72 | 1.80 | 1.00 |
| Growth & Yield | |||||
| Revenue Growth | -6.5% | -6.5% | -6.4% | 6.7% | — |
| EPS Growth | 25.5% | 25.5% | -180.3% | 58.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+85.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.95 → -0.71
Residual
+85.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.